174 related articles for article (PubMed ID: 16616575)
1. Bisphosphonate therapy in rheumatoid arthritis.
Breuil V; Euller-Ziegler L
Joint Bone Spine; 2006 Jul; 73(4):349-54. PubMed ID: 16616575
[TBL] [Abstract][Full Text] [Related]
2. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
Suzuki Y
Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
[TBL] [Abstract][Full Text] [Related]
3. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
4. [Biological effects of bisphosphonates in patients with rheumatoid arthritis].
Nagashima M; Shu G; Yamamoto K
Nihon Rinsho; 2005 Sep; 63(9):1607-12. PubMed ID: 16164219
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.
Kinoshita H; Miyakoshi N; Kashiwagura T; Kasukawa Y; Sugimura Y; Shimada Y
Mod Rheumatol; 2017 Jul; 27(4):582-586. PubMed ID: 27659808
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis.
Azuaga-Piñango AB; Peris P
Med Clin (Barc); 2020 May; 154(9):358-365. PubMed ID: 32113698
[TBL] [Abstract][Full Text] [Related]
7. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
8. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
Tanaka Y
Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.
Wolfe F; Bolster MB; O'Connor CM; Michaud K; Lyles KW; Colón-Emeric CS
J Bone Miner Res; 2013 May; 28(5):984-91. PubMed ID: 23074131
[TBL] [Abstract][Full Text] [Related]
10. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.
Meinen R; Galli-Lysak I; Villiger PM; Aeberli D
BMC Musculoskelet Disord; 2016 Aug; 17():324. PubMed ID: 27491286
[TBL] [Abstract][Full Text] [Related]
11. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
[TBL] [Abstract][Full Text] [Related]
12. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.
Jarrett SJ; Conaghan PG; Sloan VS; Papanastasiou P; Ortmann CE; O'Connor PJ; Grainger AJ; Emery P
Arthritis Rheum; 2006 May; 54(5):1410-4. PubMed ID: 16645968
[TBL] [Abstract][Full Text] [Related]
13. Effect of rheumatoid arthritis on volumetric bone mineral density and bone geometry, assessed by peripheral quantitative computed tomography in postmenopausal women treated with bisphosphonates.
Tournis S; Samdanis V; Psarelis S; Liakou C; Antoniou J; Georgoulas T; Dontas I; Papaioannou N; Gazi S; Lyritis GP
J Rheumatol; 2012 Jun; 39(6):1215-20. PubMed ID: 22467921
[TBL] [Abstract][Full Text] [Related]
14. Hormonal preservation of bone in rheumatoid arthritis.
Bijlsma JW; Jacobs JW
Rheum Dis Clin North Am; 2000 Nov; 26(4):897-910. PubMed ID: 11084950
[TBL] [Abstract][Full Text] [Related]
15. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
16. Management of osteoporosis in rheumatoid arthritis patients.
Hoes JN; Bultink IE; Lems WF
Expert Opin Pharmacother; 2015 Mar; 16(4):559-71. PubMed ID: 25626121
[TBL] [Abstract][Full Text] [Related]
17. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
19. Alternative use of bisphosphonate therapy for rheumatic disease.
Le Goff B; Berthelot JM; Maugars Y; Romas E
Curr Pharm Des; 2010; 16(27):3045-52. PubMed ID: 20722620
[TBL] [Abstract][Full Text] [Related]
20. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
